Clinical trials have long been the slow, expensive bottleneck of drug development. But iNGENū CRO, led by physician and anesthesiologist Dr. Sud Agarwal, is flipping that model on its head by using a mix of global operations, automation, and strategic AI to drive down costs and timelines. Moreover, it is doing so without compromising on quality or compliance. For early-stage biopharma companies watching budgets and timelines with equal urgency, that shift could be the difference between breakthrough and burnout.
Agarwal’s firm operates primarily in the Asia-Pacific region, where trials can cost up to 90% less per patient compared to the U.S. By tapping into health systems in Australia, Malaysia, Singapore, and Mauritius, many of which follow European-style medical documentation, iNGENū can offer access to diverse populations and centralized records. That’s not just a cost advantage, it’s a data-quality win, enabling global pharma to gather real-world evidence from ethnically varied participants without overextending geographically or financially.
The efficiency isn’t just geographic, it’s digital. iNGENū applies automation and AI across nearly every touchpoint: from regulatory submissions and medical writing to patient recruitment and site selection. But unlike the hype around AI as a standalone solution, iNGENū’s implementation relies on a “human-in-the-loop” approach. The AI handles first drafts and data synthesis, while experts step in for final refinement. The result? A process that once took months, like ethics board submissions or clinical data analysis, can now be completed in days.
And in clinical trials, time is money. One recent client came to iNGENū with an almost impossible ask: get everything submitted for ethics approval within five days to unlock a new round of VC funding. Thanks to the company’s tech infrastructure and multinational team, they pulled it off. It’s a clear example of how iNGENū isn’t just making research more affordable, it’s making it more responsive to the speed of modern innovation.
The ability to launch quickly across multiple jurisdictions also gives sponsors access to patient pools that might be inaccessible or too costly to reach in the U.S. With support from government R&D incentives, like Australia’s program offering up to 43.5% back on clinical costs, iNGENū clients are increasingly early-stage U.S. and European biotechs looking to stretch their dollars and move faster. Places like Mauritius, with its ethnically diverse population and reliable medical infrastructure, are helping fill a critical need for global representation in data, something regulators and markets are demanding more of.
Recruitment remains one of the toughest hurdles in clinical trials, especially in the U.S., where marketing campaigns are often required just to find eligible participants. iNGENū’s AI tools help map out which sites are likely to recruit fastest based on historical performance and population data. Instead of guessing where to run a trial, sponsors can strategically target clinics and hospitals with the highest likelihood of success, without wasting time or patient goodwill.
What’s changing here isn’t just the pace or cost structure of clinical trials. It’s the entire philosophy. iNGENū isn’t trying to cut corners or bypass regulations. It’s building a system where compliance, quality, speed, and cost efficiency don’t have to be at odds. With digital-native infrastructure, multinational operations, and a practical understanding of both medicine and innovation, the firm is turning what was once a $1 billion, multi-year challenge into a more accessible, streamlined pathway for drug development.
For companies racing to bring new treatments to market, iNGENū may be less of a vendor and more of an acceleration strategy.
Want more Innovation Saves Lives? Check out the articles or head over to Apple Podcasts.
